UK's Hikma Pharmaceuticals reiterates 2026 outlook despite higher costs from Iran war
23/04/2026 07:24
April 23 (Reuters) - Hikma Pharmaceuticals HIK.L reiterated its 2026 guidance on Thursday, adding that, while it has faced some pressure on shipping, energy, and insurance costs due to the war in the Middle East, a key market for the firm, it was confident it could absorb the higher costs. (Reporting by Neeshita Beura in Bengaluru; Editing by Rashmi Aich) ((Neeshita.Beura@thomsonreuters.com))